All 0 3 0 3 B-gender
females 4 11 4 11 I-gender
of 12 14 12 14 O
childbearing 15 27 15 27 O
potential 28 37 28 37 O
must 38 42 38 42 O
have 43 47 43 47 O
a 48 49 48 49 O
blood 50 55 50 55 O
test 56 60 56 60 O
or 61 63 61 63 O
urine 64 69 64 69 O
study 70 75 70 75 O
within 76 82 76 82 O
7 83 84 83 84 B-upper_bound
days 85 89 85 89 I-upper_bound
prior 90 95 90 95 I-upper_bound
to 96 98 96 98 O
FES 99 102 99 102 B-treatment
PET 103 106 103 106 I-treatment
/ 106 107 106 107 O
CT 107 109 107 109 B-treatment
scan 110 114 110 114 I-treatment
and 115 118 115 118 O
[ 119 120 119 120 B-treatment
18F]-fluorodeoxyglucose 120 143 120 143 I-treatment
( 144 145 144 145 I-treatment
FDG)-PET 145 153 145 153 I-treatment
/ 153 154 153 154 O
CT 154 156 154 156 O
scan 157 161 157 161 O
to 162 164 162 164 O
rule 165 169 165 169 O
out 170 173 170 173 O
pregnancy 174 183 174 183 B-pregnancy

Disease 0 7 184 191 O
may 8 11 192 195 O
be 12 14 196 198 O
measurable 15 25 199 209 O
( 26 27 210 211 O
by 27 29 211 213 O
Response 30 38 214 222 O
Evaluation 39 49 223 233 O
Criteria 50 58 234 242 O
in 59 61 243 245 O
Solid 62 67 246 251 O
Tumors 68 74 252 258 O
[ 75 76 259 260 O
RECIST 76 82 260 266 O
] 82 83 266 267 O
1.1 84 87 268 271 O
criteria 88 96 272 280 O
) 96 97 280 281 O
or 98 100 282 284 O
non 101 104 285 288 O
- 104 105 288 289 O
measurable 105 115 289 299 O
but 116 119 300 303 O
must 120 124 304 308 O
be 125 127 309 311 O
present 128 135 312 319 O
in 136 138 320 322 O
at 139 141 323 325 O
least 142 147 326 331 O
one 148 151 332 335 B-lower_bound
non 152 155 336 339 O
- 155 156 339 340 O
liver 156 161 340 345 O
site 162 166 346 350 O
, 166 167 350 351 O
where 168 173 352 357 O
presence 174 182 358 366 O
is 183 185 367 369 O
defined 186 193 370 377 O
as 194 196 378 380 O
1.5 197 200 381 384 B-lower_bound
cm 201 203 385 387 I-lower_bound
or 204 206 388 390 O
greater 207 214 391 398 O
and 215 218 399 402 O
visualized 219 229 403 413 O
on 230 232 414 416 O
PET 233 236 417 420 B-treatment
/ 236 237 420 421 I-treatment
CT 237 239 421 423 I-treatment
with 240 244 424 428 I-treatment
[ 245 246 429 430 I-treatment
18F]-fluorodeoxyglucose 246 269 430 453 I-treatment
( 270 271 454 455 I-treatment
FDG 271 274 455 458 I-treatment
) 274 275 458 459 I-treatment

Has 0 3 460 463 O
not 4 7 464 467 O
been 8 12 468 472 O
naturally 13 22 473 482 O
postmenopausal 23 37 483 497 O
for 38 41 498 501 O
at 42 44 502 504 O
least 45 50 505 510 O
24 51 53 511 513 B-lower_bound
consecutive 54 65 514 525 I-lower_bound
months 66 72 526 532 I-lower_bound
( 73 74 533 534 O
i.e. 74 78 534 538 O
, 78 79 538 539 O
has 80 83 540 543 O
had 84 87 544 547 O
menses 88 94 548 554 O
at 95 97 555 557 O
any 98 101 558 561 O
time 102 106 562 566 O
in 107 109 567 569 O
the 110 113 570 573 O
preceding 114 123 574 583 B-upper_bound
24 124 126 584 586 I-upper_bound
consecutive 127 138 587 598 I-upper_bound
months 139 145 599 605 I-upper_bound
) 145 146 605 606 O

Has 0 3 607 610 O
not 4 7 611 614 O
undergone 8 17 615 624 O
a 18 19 625 626 O
hysterectomy 20 32 627 639 B-treatment
or 33 35 640 642 O
bilateral 36 45 643 652 B-treatment
oophorectomy 46 58 653 665 I-treatment

Histologically 0 14 666 680 O
confirmed 15 24 681 690 O
metastatic 25 35 691 701 B-cancer
breast 36 42 702 708 I-cancer
cancer 43 49 709 715 I-cancer

Life 0 4 716 720 B-clinical_variable
expectancy 5 15 721 731 I-clinical_variable
must 16 20 732 736 O
be 21 23 737 739 O
estimated 24 33 740 749 O
by 34 36 750 752 O
patient 37 44 753 760 O
's 44 46 760 762 O
physician 47 56 763 772 O
at 57 59 773 775 O
> 60 61 776 777 O
6 62 63 778 779 B-lower_bound
months 64 70 780 786 I-lower_bound

Patient 0 7 787 794 O
is 8 10 795 797 O
a 11 12 798 799 O
postmenopausal 13 27 800 814 O
woman 28 33 815 820 B-gender
, 33 34 820 821 O
man 35 38 822 825 O
, 38 39 825 826 O
or 40 42 827 829 O
premenopausal 43 56 830 843 O
woman 57 62 844 849 O
for 63 66 850 853 O
whom 67 71 854 858 O
standard 72 80 859 867 B-treatment
endocrine 81 90 868 877 I-treatment
therapy 91 98 878 885 I-treatment
alone 99 104 886 891 O
( 105 106 892 893 O
tamoxifen 106 115 893 902 B-treatment
, 115 116 902 903 O
aromatase 117 126 904 913 B-gender
inhibitor 127 136 914 923 I-gender
[ 137 138 924 925 I-gender
AI 138 140 925 927 I-gender
] 140 141 927 928 I-gender
, 141 142 928 929 O
with 143 147 930 934 O
or 148 150 935 937 O
without 151 158 938 945 O
ovarian 159 166 946 953 B-treatment
suppression 167 178 954 965 I-treatment
or 179 181 966 968 O
fulvestrant 182 193 969 980 B-treatment
) 193 194 980 981 O
is 195 197 982 984 O
planned 198 205 985 992 O
after 206 211 993 998 O
FES 212 215 999 1002 O
- 215 216 1002 1003 O
PET 216 219 1003 1006 O
/ 219 220 1006 1007 O
CT 220 222 1007 1009 O
is 223 225 1010 1012 O
completed 226 235 1013 1022 O

Patient 0 7 1023 1030 O
is 8 10 1031 1033 O
not 11 14 1034 1037 O
now 15 18 1038 1041 O
, 18 19 1041 1042 O
and 20 23 1043 1046 O
never 24 29 1047 1052 O
has 30 33 1053 1056 O
received 34 42 1057 1065 O
adjuvant 43 51 1066 1074 B-treatment
endocrine 52 61 1075 1084 I-treatment
therapy 62 69 1085 1092 I-treatment
OR 70 72 1093 1095 O
patient 73 80 1096 1103 O
is 81 83 1104 1106 O
currently 84 93 1107 1116 O
receiving 94 103 1117 1126 O
or 104 106 1127 1129 O
has 107 110 1130 1133 O
received 111 119 1134 1142 O
adjuvant 120 128 1143 1151 O
endocrine 129 138 1152 1161 O
therapy 139 146 1162 1169 O
in 147 149 1170 1172 O
the 150 153 1173 1176 O
past 154 158 1177 1181 O

Patient 0 7 1182 1189 O
must 8 12 1190 1194 O
NOT 13 16 1195 1198 O
be 17 19 1199 1201 O
in 20 22 1202 1204 O
liver 23 28 1205 1210 B-chronic_disease
failure 29 36 1211 1218 I-chronic_disease
as 37 39 1219 1221 O
judged 40 46 1222 1228 O
by 47 49 1229 1231 O
the 50 53 1232 1235 O
patient 54 61 1236 1243 O
's 61 63 1243 1245 O
physician 64 73 1246 1255 O

Patient 0 7 1256 1263 O
must 8 12 1264 1268 O
NOT 13 16 1269 1272 O
be 17 19 1273 1275 O
planning 20 28 1276 1284 O
to 29 31 1285 1287 O
receive 32 39 1288 1295 O
molecular 40 49 1296 1305 B-treatment
targeted 50 58 1306 1314 I-treatment
therapy 59 66 1315 1322 I-treatment
( 67 68 1323 1324 O
such 68 72 1324 1328 O
as 73 75 1329 1331 O
everolimus 76 86 1332 1342 B-treatment
or 87 89 1343 1345 O
palbociclib 90 101 1346 1357 B-treatment
) 101 102 1357 1358 O
nor 103 106 1359 1362 O
HER2 107 111 1363 1367 B-treatment
directed 112 120 1368 1376 I-treatment
therapy 121 128 1377 1384 I-treatment
in 129 131 1385 1387 O
addition 132 140 1388 1396 O
to 141 143 1397 1399 O
endocrine 144 153 1400 1409 B-treatment
therapy 154 161 1410 1417 I-treatment

Patient 0 7 1418 1425 O
must 8 12 1426 1430 O
NOT 13 16 1431 1434 O
have 17 21 1435 1439 O
a 22 23 1440 1441 O
history 24 31 1442 1449 O
of 32 34 1450 1452 O
> 35 36 1453 1454 O
1 37 38 1455 1456 B-lower_bound
line 39 43 1457 1461 O
of 44 46 1462 1464 O
administered 47 59 1465 1477 O
chemotherapy 60 72 1478 1490 B-treatment
for 73 76 1491 1494 O
metastatic 77 87 1495 1505 B-cancer
disease 88 95 1506 1513 O
and 96 99 1514 1517 O
must 100 104 1518 1522 O
be 105 107 1523 1525 O
off 108 111 1526 1529 O
chemotherapy 112 124 1530 1542 O
for 125 128 1543 1546 O
a 129 130 1547 1548 O
minimum 131 138 1549 1556 O
of 139 141 1557 1559 O
2 142 143 1560 1561 B-lower_bound
weeks 144 149 1562 1567 I-lower_bound
; 149 150 1567 1568 O
prior 151 156 1569 1574 B-treatment
chemotherapy 157 169 1575 1587 I-treatment
in 170 172 1588 1590 I-treatment
the 173 176 1591 1594 I-treatment
adjuvant 177 185 1595 1603 I-treatment
setting 186 193 1604 1611 I-treatment
is 194 196 1612 1614 O
allowed 197 204 1615 1622 O

Patient 0 7 1623 1630 O
must 8 12 1631 1635 O
NOT 13 16 1636 1639 O
have 17 21 1640 1644 O
a 22 23 1645 1646 O
history 24 31 1647 1654 O
of 32 34 1655 1657 O
allergic 35 43 1658 1666 O
reaction 44 52 1667 1675 O
attributable 53 65 1676 1688 O
to 66 68 1689 1691 O
compounds 69 78 1692 1701 O
of 79 81 1702 1704 O
similar 82 89 1705 1712 O
chemical 90 98 1713 1721 O
or 99 101 1722 1724 O
biologic 102 110 1725 1733 O
composition 111 122 1734 1745 O
to 123 125 1746 1748 O
18F 126 129 1749 1752 B-allergy_name
- 129 130 1752 1753 I-allergy_name
FES 130 133 1753 1756 I-allergy_name

Patient 0 7 1757 1764 O
must 8 12 1765 1769 O
NOT 13 16 1770 1773 O
have 17 21 1774 1778 O
human 22 27 1779 1784 O
epidermal 28 37 1785 1794 O
growth 38 44 1795 1801 O
factor-2 45 53 1802 1810 O
positive 54 62 1811 1819 O
( 63 64 1820 1821 O
HER2 64 68 1821 1825 B-cancer
+ 68 69 1825 1826 I-cancer
) 69 70 1826 1827 O
metastatic 71 81 1828 1838 B-cancer
disease 82 89 1839 1846 I-cancer

Patient 0 7 1847 1854 O
must 8 12 1855 1859 O
NOT 13 16 1860 1863 O
have 17 21 1864 1868 O
received 22 30 1869 1877 O
prior 31 36 1878 1883 B-treatment
endocrine 37 46 1884 1893 I-treatment
therapy 47 54 1894 1901 I-treatment
for 55 58 1902 1905 O
metastatic 59 69 1906 1916 B-cancer
disease 70 77 1917 1924 I-cancer
( 78 79 1925 1926 O
i.e. 79 83 1926 1930 O
, 83 84 1930 1931 O
must 85 89 1932 1936 O
be 90 92 1937 1939 O
first 93 98 1940 1945 B-treatment
- 98 99 1945 1946 I-treatment
line 99 103 1946 1950 I-treatment
endocrine 104 113 1951 1960 I-treatment
therapy 114 121 1961 1968 I-treatment
for 122 125 1969 1972 O
metastatic 126 136 1973 1983 O
disease 137 144 1984 1991 O
) 144 145 1991 1992 O

Patient 0 7 1993 2000 O
must 8 12 2001 2005 O
NOT 13 16 2006 2009 O
weigh 17 22 2010 2015 O
more 23 27 2016 2020 O
than 28 32 2021 2025 O
the 33 36 2026 2029 O
maximum 37 44 2030 2037 O
weight 45 51 2038 2044 B-clinical_variable
limit 52 57 2045 2050 O
for 58 61 2051 2054 O
the 62 65 2055 2058 O
table 66 71 2059 2064 O
for 72 75 2065 2068 O
the 76 79 2069 2072 O
PET 80 83 2073 2076 O
/ 83 84 2076 2077 O
CT 84 86 2077 2079 O
scanner 87 94 2080 2087 O
at 95 97 2088 2090 O
the 98 101 2091 2094 O
institution 102 113 2095 2106 O
where 114 119 2107 2112 O
the 120 123 2113 2116 O
study 124 129 2117 2122 O
is 130 132 2123 2125 O
being 133 138 2126 2131 O
performed 139 148 2132 2141 O

Patient 0 7 2142 2149 O
must 8 12 2150 2154 O
be 13 15 2155 2157 O
able 16 20 2158 2162 O
to 21 23 2163 2165 O
lie 24 27 2166 2169 O
still 28 33 2170 2175 O
for 34 37 2176 2179 O
a 38 39 2180 2181 O
20 40 42 2182 2184 B-lower_bound
- 42 43 2184 2185 O
30 43 45 2185 2187 B-upper_bound
minute 46 52 2188 2194 I-upper_bound
PET 53 56 2195 2198 B-treatment
/ 56 57 2198 2199 I-treatment
CT 57 59 2199 2201 I-treatment
scan 60 64 2202 2206 I-treatment

Patients 0 8 2207 2215 O
must 9 13 2216 2220 O
have 14 18 2221 2225 O
an 19 21 2226 2228 O
Eastern 22 29 2229 2236 B-clinical_variable
Cooperative 30 41 2237 2248 I-clinical_variable
Oncology 42 50 2249 2257 I-clinical_variable
Group 51 56 2258 2263 I-clinical_variable
( 57 58 2264 2265 I-clinical_variable
ECOG 58 62 2265 2269 I-clinical_variable
) 62 63 2269 2270 I-clinical_variable
performance 64 75 2271 2282 I-clinical_variable
status 76 82 2283 2289 I-clinical_variable
of 83 85 2290 2292 O
0 86 87 2293 2294 B-lower_bound
- 87 88 2294 2295 O
3 88 89 2295 2296 B-upper_bound
( 90 91 2297 2298 O
restricted 91 101 2298 2308 O
to 102 104 2309 2311 O
ECOG 105 109 2312 2316 B-clinical_variable
performance 110 121 2317 2328 I-clinical_variable
status 122 128 2329 2335 I-clinical_variable
[ 129 130 2336 2337 I-clinical_variable
PS 130 132 2337 2339 I-clinical_variable
] 132 133 2339 2340 I-clinical_variable
0 134 135 2341 2342 O
- 135 136 2342 2343 O
2 136 137 2343 2344 B-upper_bound
if 138 140 2345 2347 O
age 141 144 2348 2351 B-age
> 145 146 2352 2353 O
70 147 149 2354 2356 B-lower_bound
years 150 155 2357 2362 I-lower_bound
) 155 156 2362 2363 O

Primary 0 7 2364 2371 B-cancer
tumor 8 13 2372 2377 I-cancer
and/or 14 20 2378 2384 O
metastatic 21 31 2385 2395 O
site 32 36 2396 2400 O
must 37 41 2401 2405 O
be 42 44 2406 2408 O
ER+ 45 48 2409 2412 O
and 49 52 2413 2416 O
may 53 56 2417 2420 O
be 57 59 2421 2423 O
progesterone 60 72 2424 2436 O
- 72 73 2436 2437 O
receptor 73 81 2437 2445 O
positive 82 90 2446 2454 O
( 91 92 2455 2456 O
PgR+ 92 96 2456 2460 O
) 96 97 2460 2461 O
or 98 100 2462 2464 O
progesterone 101 113 2465 2477 O
- 113 114 2477 2478 O
receptor 114 122 2478 2486 O
negative 123 131 2487 2495 O
( 132 133 2496 2497 O
PgR- 133 137 2497 2501 O
) 137 138 2501 2502 O
by 139 141 2503 2505 O
IHC 142 145 2506 2509 B-treatment

The 0 3 2510 2513 O
pathology 4 13 2514 2523 O
report 14 20 2524 2530 O
and 21 24 2531 2534 O
either 25 31 2535 2541 O
( 32 33 2542 2543 O
1 33 34 2543 2544 O
) 34 35 2544 2545 O
tissue 36 42 2546 2552 O
( 43 44 2553 2554 O
blocks 44 50 2554 2560 O
or 51 53 2561 2563 O
an 54 56 2564 2566 O
unstained 57 66 2567 2576 O
slides 67 73 2577 2583 O
) 73 74 2583 2584 O
or 75 77 2585 2587 O
( 78 79 2588 2589 O
2 79 80 2589 2590 O
) 80 81 2590 2591 O
a 82 83 2592 2593 O
photomicrograph 84 99 2594 2609 O
of 100 102 2610 2612 O
the 103 106 2613 2616 O
ER 107 109 2617 2619 O
IHC 110 113 2620 2623 O
slides 114 120 2624 2630 O
from 121 125 2631 2635 O
at 126 128 2636 2638 O
least 129 134 2639 2644 O
one 135 138 2645 2648 B-lower_bound
site 139 143 2649 2653 O
of 144 146 2654 2656 O
metastatic 147 157 2657 2667 B-cancer
disease 158 165 2668 2675 I-cancer
and/or 166 172 2676 2682 O
from 173 177 2683 2687 O
primary 178 185 2688 2695 B-cancer
breast 186 192 2696 2702 I-cancer
cancer 193 199 2703 2709 I-cancer
must 200 204 2710 2714 O
be 205 207 2715 2717 O
available 208 217 2718 2727 O
for 218 221 2728 2731 O
central 222 229 2732 2739 O
review 230 236 2740 2746 O
and 237 240 2747 2750 O
analysis 241 249 2751 2759 O

Women 0 5 2760 2765 B-gender
must 6 10 2766 2770 O
not 11 14 2771 2774 B-pregnancy
be 15 17 2775 2777 I-pregnancy
pregnant 18 26 2778 2786 I-pregnancy
or 27 29 2787 2789 O
breast 30 36 2790 2796 O
- 36 37 2796 2797 O
feeding 37 44 2797 2804 O

Women 0 5 2805 2810 B-gender
of 6 8 2811 2813 O
childbearing 9 21 2814 2826 O
potential 22 31 2827 2836 O
and 32 35 2837 2840 O
sexually 36 44 2841 2849 O
active 45 51 2850 2856 O
males 52 57 2857 2862 B-gender
must 58 62 2863 2867 O
use 63 66 2868 2871 B-contraception_consent
an 67 69 2872 2874 I-contraception_consent
accepted 70 78 2875 2883 I-contraception_consent
and 79 82 2884 2887 I-contraception_consent
effective 83 92 2888 2897 I-contraception_consent
method 93 99 2898 2904 I-contraception_consent
of 100 102 2905 2907 I-contraception_consent
contraception 103 116 2908 2921 I-contraception_consent
or 117 119 2922 2924 O
to 120 122 2925 2927 O
abstain 123 130 2928 2935 O
from 131 135 2936 2940 O
sexual 136 142 2941 2947 O
intercourse 143 154 2948 2959 O
for 155 158 2960 2963 O
the 159 162 2964 2967 O
duration 163 171 2968 2976 O
of 172 174 2977 2979 O
their 175 180 2980 2985 O
participation 181 194 2986 2999 O
in 195 197 3000 3002 O
the 198 201 3003 3006 O
study 202 207 3007 3012 O

a 0 1 3013 3014 O
female 2 8 3015 3021 B-gender
of 9 11 3022 3024 O
childbearing 12 24 3025 3037 O
potential 25 34 3038 3047 O
is 35 37 3048 3050 O
any 38 41 3051 3054 O
woman 42 47 3055 3060 B-gender
, 47 48 3060 3061 O
regardless 49 59 3062 3072 O
of 60 62 3073 3075 O
sexual 63 69 3076 3082 O
orientation 70 81 3083 3094 O
or 82 84 3095 3097 O
whether 85 92 3098 3105 O
they 93 97 3106 3110 O
have 98 102 3111 3115 O
undergone 103 112 3116 3125 O
tubal 113 118 3126 3131 O
ligation 119 127 3132 3140 O

adjuvant 0 8 3141 3149 B-treatment
endocrine 9 18 3150 3159 I-treatment
therapy 19 26 3160 3167 I-treatment
was 27 30 3168 3171 O
initiated 31 40 3172 3181 O
> 41 42 3182 3183 O
2 43 44 3184 3185 B-lower_bound
years 45 50 3186 3191 I-lower_bound
prior 51 56 3192 3197 I-lower_bound
to 57 59 3198 3200 O
diagnosis 60 69 3201 3210 O
of 70 72 3211 3213 O
metastatic 73 83 3214 3224 B-cancer
disease 84 91 3225 3232 I-cancer

patient 0 7 3233 3240 O
is 8 10 3241 3243 O
not 11 14 3244 3247 O
receiving 15 24 3248 3257 O
blocking 25 33 3258 3266 O
adjuvant 34 42 3267 3275 B-treatment
therapy 43 50 3276 3283 I-treatment
( 51 52 3284 3285 O
such 52 56 3285 3289 O
as 57 59 3290 3292 O
toremifene 60 70 3293 3303 B-treatment
or 71 73 3304 3306 O
tamoxifen 74 83 3307 3316 B-treatment
) 83 84 3316 3317 O
OR 85 87 3318 3320 O
patient 88 95 3321 3328 O
is 96 98 3329 3331 O
receiving 99 108 3332 3341 O
blocking 109 117 3342 3350 O
adjuvant 118 126 3351 3359 O
therapy 127 134 3360 3367 O
, 134 135 3367 3368 O
but 136 139 3369 3372 O
will 140 144 3373 3377 O
stop 145 149 3378 3382 O
this 150 154 3383 3387 O
therapy 155 162 3388 3395 O
a 163 164 3396 3397 O
minimum 165 172 3398 3405 O
of 173 175 3406 3408 O
60 176 178 3409 3411 B-lower_bound
days 179 183 3412 3416 I-lower_bound
prior 184 189 3417 3422 I-lower_bound
to 190 192 3423 3425 O
FES 193 196 3426 3429 B-treatment
- 196 197 3429 3430 I-treatment
PET 197 200 3430 3433 I-treatment
/ 200 201 3433 3434 I-treatment
CT 201 203 3434 3436 I-treatment
while 204 209 3437 3442 O
still 210 215 3443 3448 O
complying 216 225 3449 3458 O
with 226 230 3459 3463 O
the 231 234 3464 3467 O
study 235 240 3468 3473 O
timeline 241 249 3474 3482 O

patients 0 8 3483 3491 O
who 9 12 3492 3495 O
developed 13 22 3496 3505 O
metastatic 23 33 3506 3516 B-chronic_disease
disease 34 41 3517 3524 I-chronic_disease
while 42 47 3525 3530 O
still 48 53 3531 3536 O
receiving 54 63 3537 3546 O
adjuvant 64 72 3547 3555 B-treatment
endocrine 73 82 3556 3565 I-treatment
therapy 83 90 3566 3573 I-treatment
must 91 95 3574 3578 O
have 96 100 3579 3583 O
a 101 102 3584 3585 O
planned 103 110 3586 3593 O
change 111 117 3594 3600 O
in 118 120 3601 3603 O
the 121 124 3604 3607 O
type 125 129 3608 3612 O
of 130 132 3613 3615 O
endocrine 133 142 3616 3625 B-treatment
agent 143 148 3626 3631 I-treatment
used 149 153 3632 3636 O
for 154 157 3637 3640 O
subsequent 158 168 3641 3651 B-treatment
metastatic 169 179 3652 3662 I-treatment
disease 180 187 3663 3670 I-treatment
treatment 188 197 3671 3680 I-treatment

patients 0 8 3681 3689 O
with 9 13 3690 3694 O
a 14 15 3695 3696 O
history 16 23 3697 3704 O
of 24 26 3705 3707 O
an 27 29 3708 3710 O
estrogen 30 38 3711 3719 B-cancer
- 38 39 3719 3720 I-cancer
receptor 39 47 3720 3728 I-cancer
negative 48 56 3729 3737 I-cancer
( 57 58 3738 3739 I-cancer
ER- 58 61 3739 3742 I-cancer
) 61 62 3742 3743 I-cancer
primary 63 70 3744 3751 I-cancer
tumor 71 76 3752 3757 I-cancer
and 77 80 3758 3761 O
a 81 82 3762 3763 O
documented 83 93 3764 3774 O
ER+ 94 97 3775 3778 O
metastatic 98 108 3779 3789 O
site 109 113 3790 3794 O

